Epileptic seizure

Emmes Employees Contribute to New England Journal of Medicine Report on Pregnant Women with Epilepsy

Retrieved on: 
Monday, February 8, 2021
Epilepsy, Medicine, Health, Clinical medicine, Epileptic seizure, Epilepsy syndromes, Frontal lobe epilepsy

"The research addressed the important issue of how to care for women with epilepsy during pregnancy and postpartum," said Dr. Wilson, who leads Emmes' neurology and mental health research unit.

Key Points: 
  • "The research addressed the important issue of how to care for women with epilepsy during pregnancy and postpartum," said Dr. Wilson, who leads Emmes' neurology and mental health research unit.
  • "It is one of the first studies to compare seizure frequency of pregnant women with epilepsy with a non-pregnant control group.
  • One conclusion of the study was that the percentage of women with epilepsy with a higher incidence of seizures during pregnancy was similar to that in women with epilepsy who were not pregnant.
  • The study findings suggest pregnancy may not make seizures worse among women with epilepsy whose seizure medication is carefully managed.

New Coalition Launches to Promote Importance of Seizure Emergency Plans

Retrieved on: 
Sunday, November 1, 2020
Epilepsy, Epileptic seizure, Epilepsy in animals, Medicine, Clinical medicine, Health, Generalized tonic–clonic seizure, Seizure types

WASHINGTON, Nov. 1, 2020 /PRNewswire/ --Today in concert with Epilepsy Awareness Month, a collaboration of three non-profit organizations announced the launch of the Seizure Action Plan (SAP) Coalition to educate people with epilepsy, their caregivers and healthcare professionals about seizure emergency rescue protocols and the importance of personalized seizure action plans.

Key Points: 
  • WASHINGTON, Nov. 1, 2020 /PRNewswire/ --Today in concert with Epilepsy Awareness Month, a collaboration of three non-profit organizations announced the launch of the Seizure Action Plan (SAP) Coalition to educate people with epilepsy, their caregivers and healthcare professionals about seizure emergency rescue protocols and the importance of personalized seizure action plans.
  • Many patients do not currently have seizureemergency plans and by making them a priority in their healthcare plans, they can help ensure immediate and appropriate action is taken during a seizure emergency.
  • This effort to increase education about seizure emergency plans is critical so every family can be prepared to act quickly to halt seizures that won't stop on their own."
  • "The use of seizure rescue plans is a vital component of managing seizure emergencies.

Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9

Retrieved on: 
Thursday, October 29, 2020
Health, Neurological disorders, Clinical medicine, Syndromes, Lennox–Gastaut syndrome, Dravet syndrome, Epilepsy, Fenfluramine, Epileptic seizure, Epilepsy syndromes, Epilepsy-intellectual disability in females

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
  • The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.
  • MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Epilepsy Foundation Kicks Off National Epilepsy Awareness Month with New Community Blog and Camila Coelho Sweepstakes

Retrieved on: 
Monday, October 26, 2020
Epilepsy, Medicine, Clinical medicine, Health, Epileptic seizure

The winner will get some "glam" tips from Camila and ask her questions about her epilepsy journey.

Key Points: 
  • The winner will get some "glam" tips from Camila and ask her questions about her epilepsy journey.
  • "My biggest goal is to use my story to educate our society and community about epilepsy and seizures," said Camila.
  • The Epilepsy Foundation is also unveiling a new community blog called eJourney, which features stories from around the country of people living with epilepsy.
  • With a network of nearly 50 partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy.

Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10

Retrieved on: 
Monday, October 26, 2020
Health, Neurological disorders, Clinical medicine, Syndromes, Lennox–Gastaut syndrome, Dravet syndrome, Epilepsy, Fenfluramine, Epileptic seizure, Epilepsy syndromes, Epilepsy-intellectual disability in females

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.

Key Points: 
  • Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
  • The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.
  • The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder.
  • MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli®, the World's First Automated Video and Audio-Based Seizure Monitoring System

Retrieved on: 
Thursday, October 22, 2020
Medical specialties, Medicine, Clinical medicine, Epileptic seizure, RTT, Epilepsy, Monitoring, Peltola

This is the first Breakthrough Device designation for a seizure diagnostic monitoring system.

Key Points: 
  • This is the first Breakthrough Device designation for a seizure diagnostic monitoring system.
  • "Seizure identification and quantification are the foundation of any effective treatment plan," said Neuro Event Labs' CEO, Kaapo Annala.
  • "For a seizure monitoring system to be effective, it must be easy for patients to use," said Jukka Peltola, M.D., PhD, Medical Director & Co-founder of Neuro Event Labs.
  • Neuro Event Labs has partnered with leading research hospitals and pharmaceutical companies around the world to advance epilepsy care with Nelli.

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

Retrieved on: 
Tuesday, October 20, 2020
Medical Supplies, Hospitals, FDA, Diabetes, Clinical trials, Other Health, Biotechnology, Managed care, Pharmaceutical, Health, Health, RTT, Clinical medicine, Medicine, Epilepsy, GABAA receptor positive allosteric modulators, Chloroarenes, Anxiolytics, Diazepam, Dravet syndrome, Epileptic seizure, Food and Drug Administration, Diazepam, Acute Repetitive Seizures, Xeris Pharmaceuticals, Inc.

Xeris XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.

Key Points: 
  • Xeris XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.
  • "The FDA's Fast Track designation highlights the clear unmet need in treating acute repetitive seizures with the preparations of diazepam available today and highlights our opportunity to dramatically improve care through the introduction of a ready-to-use injection formulation," said Paul R. Edick, Xeris Chairman and Chief Executive Officer.
  • As previously announced, complete results of the Phase 1b study were shared with the US FDA in an End-of-Phase 1 interaction.
  • The FDA provided feedback that Xeris drug development program for XP-0863 could advance directly into a Phase 3 registration study in both pediatric and adult patients with epilepsy.

Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2020 Financial Results on November 9, 2020

Retrieved on: 
Tuesday, October 20, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, GABAA receptor positive allosteric modulators, Chemical compounds, RTT, Anticonvulsants, Organic compounds, Chemistry, Ketones, Pregnanes, Ganaxolone, Allosteric modulator, Epileptic seizure, Allosteric regulation

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company intends to initiate a Phase 3 trial in status epilepticus.

Marinus Pharmaceuticals Participates in Upcoming Investor Healthcare Conferences

Retrieved on: 
Monday, October 19, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, GABAA receptor positive allosteric modulators, Ketones, Neurosteroids, Pregnanes, Chemical compounds, Anticonvulsants, Ganaxolone, Chemistry, Branches of biology, CDKL5, Allosteric regulation, Epileptic seizure

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy.
  • The company intends to initiate a Phase 3 trial in status epilepticus.

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

Retrieved on: 
Friday, October 16, 2020
RTT, Drugs, Clinical medicine, Health, Anxiolytics, Benzodiazepines, Chloroarenes, Diazepam, Epileptic seizure, Epilepsy, Poster session

SAN DIEGO, Oct. 16, 2020 /PRNewswire/ -- Neurelis, Inc., announced today the company has four posters being presented at the 16th annual International Child Neurology Association Congress/49th annual Child Neurology Society Meeting.

Key Points: 
  • SAN DIEGO, Oct. 16, 2020 /PRNewswire/ -- Neurelis, Inc., announced today the company has four posters being presented at the 16th annual International Child Neurology Association Congress/49th annual Child Neurology Society Meeting.
  • Neurelis Chief Medical Officer Enrique Carrazana, M.D., said the poster presentations continue to validate the safety, pharmacokinetics, and tolerability of VALTOCO (diazepam nasal spray) in children with epilepsy aged 6 and older.
  • "The data continue to demonstrate that VALTOCO is an important treatment option for children with epilepsy suffering from seizure clusters,"Dr. Carrazana said.
  • The details for the poster presentations are as follows and are available online here ; type VALTOCO in search bar to view.